By PPN News Staff
The FDA granted supplemental approval of a multidose vial of Influenza A(H5N1) Monovalent Vaccine, Adjuvanted (Audenz, Seqirus), the first adjuvanted, cell-based influenza vaccine designed to help protect people 6 months of age and older against influenza A(H5N1) in the event of a pandemic.
The approval marks an important milestone in pandemic preparedness, the company said. “Producing Audenz in multidose vials allows for increased speed and efficiency, which is absolutely